- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Advocacy
- Careers
- About
- For Pain Patients and Professionals
Osteoarthritis pain is a chronic disabling condition lacking effective treatment. Continuous use of opioid drugs during osteoarthritis pain induces tolerance and may result in dose escalation and abuse. Sigma-1 receptor (σ1R), a chaperone expressed in key areas for pain control, modulates mu-opioid receptor (MOR) activity and represents a promising target to tackle these problems. The present study investigates the efficacy of σ1R antagonist E-52862 to inhibit pain sensitization, morphine tolerance and associated electrophysiological and molecular changes in a murine model of osteoarthritis pain.